Boston Scientific Company Insiders
| BSX Stock | USD 100.69 0.82 0.81% |
Slightly above 95 percent of Boston Scientific's insiders are activelly selling. The analysis of insiders' sentiment of trading Boston Scientific Corp stock suggests that a very large number of insiders are panicking at this time. Boston Scientific employs about 53 K people. The company is managed by 39 executives with a total tenure of roughly 235 years, averaging almost 6.0 years of service per executive, having 1358.97 employees per reported executive.
| Michael Mahoney Chairman Chairman of the Board, President, Chief Executive Officer |
| Kevin Ballinger President Executive Vice President and Global President - Interventional Cardiology |
Insider Sentiment 5
Mostly Selling
Selling | Buying |
Latest Trades
| 2025-02-24 | Jeffrey B Mirviss | Disposed 4675 @ 104.25 | View | ||
| 2025-02-19 | Daniel J Brennan | Disposed 67333 @ 105.24 | View | ||
| 2025-02-18 | John Bradley Sorenson | Disposed 2657 @ 104.41 | View | ||
| 2025-02-14 | John Bradley Sorenson | Disposed 1201 @ 106.31 | View | ||
| 2025-02-13 | John Boozman | Acquired @ 106.16 | |||
| 2025-02-12 | John Bradley Sorenson | Disposed 6389 @ 105.06 | View | ||
| 2025-02-11 | Edward J Ludwig | Disposed 12000 @ 105.48 | View | ||
| 2025-02-07 | John Bradley Sorenson | Disposed 6528 @ 104.97 | View | ||
| 2025-02-03 | Arthur C Butcher | Disposed 17313 @ 101.8 | View | ||
| 2025-01-02 | John Bradley Sorenson | Disposed 4119 @ 90.02 | View | ||
| 2024-12-10 | Joseph Michael Fitzgerald | Disposed 20 @ 89.97 | View | ||
| 2024-12-02 | Wendy Carruthers | Disposed 6983 @ 90.78 | View | ||
| 2024-11-25 | Arthur C Butcher | Disposed 14010 @ 89.27 | View | ||
| 2024-11-21 | Edward J Ludwig | Disposed 4877 @ 91.63 | View | ||
| 2024-10-07 | Michael F Mahoney | Disposed 162777 @ 84.63 | View | ||
| 2024-10-01 | Wendy Carruthers | Disposed 6983 @ 83.86 | View | ||
| 2024-09-03 | Wendy Carruthers | Disposed 6983 @ 81.7 | View |
Monitoring Boston Scientific's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Boston Scientific's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Boston Scientific Corp. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Boston Scientific's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Boston |
Boston Scientific's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Boston Scientific's future performance. Based on our forecasts, it is anticipated that Boston will maintain a workforce of slightly above 53000 employees by April 2025.Boston Scientific's latest congressional trading
Congressional trading in companies like Boston Scientific Corp, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Boston Scientific by those in governmental positions are based on the same information available to the general public.
| 2025-03-07 | Representative Gil Cisneros | Acquired Under $15K | Verify | ||
| 2025-03-05 | Senator John Boozman | Acquired Under $15K | Verify | ||
| 2023-10-31 | Senator Markwayne Mullin | Acquired Under $15K | Verify | ||
| 2023-10-11 | Senator Markwayne Mullin | Acquired $15K to $50K | Verify | ||
| 2022-11-05 | Representative Alan S Lowenthal | Acquired Under $15K | Verify | ||
| 2022-10-29 | Representative Alan S Lowenthal | Acquired Under $15K | Verify | ||
| 2021-02-10 | Representative Alan S Lowenthal | Acquired Under $15K | Verify | ||
| 2020-03-24 | Representative Alan S Lowenthal | Acquired $0 - $1,000 | Verify |
Boston Scientific Management Team Effectiveness
The company has Return on Asset of 0.0504 % which means that on every $100 spent on assets, it made $0.0504 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0889 %, implying that it generated $0.0889 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.13 in 2025, whereas Return On Equity is likely to drop 0.07 in 2025. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 34.1 B in 2025, whereas Intangible Assets are likely to drop slightly above 5 B in 2025.Net Income Applicable To Common Shares is likely to rise to about 775.2 M in 2025, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.2 B in 2025.
Boston Scientific Workforce Comparison
Boston Scientific Corp is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 395,119. Boston Scientific retains roughly 53,000 in number of employees claiming about 13% of equities under Health Care industry.
Boston Scientific Profit Margins
The company has Net Profit Margin of 0.11 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.17 %, which entails that for every 100 dollars of revenue, it generated $0.17 of operating income.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.77 | 0.6861 |
|
|
Boston Scientific Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Boston Scientific insiders, such as employees or executives, is commonly permitted as long as it does not rely on Boston Scientific's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Boston Scientific insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-03-01 | 0.6014 | 86 | 143 | 927,758 | 839,360 |
| 2024-12-01 | 0.5 | 16 | 32 | 374,799 | 927,362 |
| 2024-09-01 | 0.8 | 16 | 20 | 356,424 | 522,963 |
| 2024-06-01 | 0.8947 | 34 | 38 | 238,446 | 521,017 |
| 2024-03-01 | 0.6544 | 89 | 136 | 1,240,350 | 955,834 |
| 2023-12-01 | 0.6522 | 15 | 23 | 322,738 | 665,225 |
| 2023-09-01 | 0.72 | 18 | 25 | 288,396 | 681,116 |
| 2023-06-01 | 1.0526 | 20 | 19 | 147,730 | 309,339 |
| 2023-03-01 | 0.6667 | 98 | 147 | 1,112,604 | 747,843 |
| 2022-12-01 | 0.2963 | 8 | 27 | 364,560 | 1,165,278 |
| 2022-09-01 | 0.3333 | 7 | 21 | 257,508 | 1,101,738 |
| 2022-06-01 | 1.5 | 15 | 10 | 118,446 | 49,307 |
| 2022-03-01 | 0.6726 | 152 | 226 | 1,493,498 | 831,014 |
| 2021-12-01 | 0.4286 | 9 | 21 | 479,057 | 960,871 |
| 2021-09-01 | 0.5897 | 23 | 39 | 820,822 | 1,545,234 |
| 2021-06-01 | 0.5 | 19 | 38 | 158,837 | 545,389 |
| 2021-03-01 | 0.7212 | 163 | 226 | 1,885,897 | 1,020,519 |
| 2020-12-01 | 0.3846 | 5 | 13 | 60,688 | 374,903 |
| 2020-09-01 | 0.2857 | 8 | 28 | 303,856 | 485,019 |
| 2020-06-01 | 1.1818 | 13 | 11 | 53,348 | 30,129 |
| 2020-03-01 | 0.6979 | 164 | 235 | 2,079,256 | 1,191,108 |
| 2019-12-01 | 0.4324 | 16 | 37 | 246,045 | 511,738 |
| 2019-09-01 | 0.3913 | 9 | 23 | 119,097 | 224,036 |
| 2019-06-01 | 0.75 | 21 | 28 | 82,708 | 160,051 |
| 2019-03-01 | 0.7018 | 153 | 218 | 2,346,276 | 1,607,760 |
| 2018-12-01 | 0.3871 | 12 | 31 | 114,341 | 458,521 |
| 2018-09-01 | 0.375 | 6 | 16 | 95,942 | 320,077 |
| 2018-06-01 | 0.6452 | 20 | 31 | 182,138 | 383,514 |
| 2018-03-01 | 0.7537 | 153 | 203 | 2,605,910 | 1,716,307 |
| 2017-12-01 | 0.5185 | 14 | 27 | 761,728 | 831,881 |
| 2017-09-01 | 0.6 | 18 | 30 | 193,602 | 451,815 |
| 2017-06-01 | 0.92 | 23 | 25 | 178,279 | 282,317 |
| 2017-03-01 | 0.8511 | 160 | 188 | 3,149,899 | 1,755,618 |
| 2016-12-01 | 0.5 | 9 | 18 | 403,658 | 654,202 |
| 2016-09-01 | 0.5625 | 9 | 16 | 174,275 | 553,178 |
| 2016-06-01 | 1.0 | 26 | 26 | 332,058 | 1,005,299 |
| 2016-03-01 | 0.8144 | 158 | 194 | 3,841,811 | 2,398,433 |
| 2015-12-01 | 0.4783 | 11 | 23 | 407,999 | 822,833 |
| 2015-09-01 | 2.75 | 11 | 4 | 540,849 | 55,137 |
| 2015-06-01 | 1.5 | 24 | 16 | 310,456 | 443,462 |
| 2015-03-01 | 0.77 | 154 | 200 | 3,785,178 | 2,542,222 |
| 2014-12-01 | 1.5 | 15 | 10 | 507,186 | 581,716 |
| 2014-09-01 | 0.4118 | 7 | 17 | 108,431 | 235,186 |
| 2014-06-01 | 0.5833 | 7 | 12 | 42,823 | 111,000 |
| 2014-03-01 | 0.8743 | 146 | 167 | 2,959,471 | 1,221,529 |
| 2013-12-01 | 0.5 | 17 | 34 | 946,371 | 2,106,860 |
| 2013-09-01 | 0.4706 | 8 | 17 | 517,873 | 1,101,745 |
| 2013-06-01 | 1.0769 | 14 | 13 | 274,607 | 110,178 |
| 2013-03-01 | 0.7688 | 123 | 160 | 3,808,593 | 950,470 |
| 2012-12-01 | 2.3333 | 14 | 6 | 398,832 | 459,392 |
| 2012-09-01 | 0.1613 | 10 | 62 | 90,749 | 11,891,140 |
| 2012-06-01 | 0.1667 | 17 | 102 | 362,273 | 20,744,265 |
| 2012-03-01 | 0.812 | 108 | 133 | 3,604,301 | 4,248,999 |
| 2011-12-01 | 1.0769 | 14 | 13 | 2,472,556 | 517,439 |
| 2011-09-01 | 0.4242 | 14 | 33 | 157,956 | 230,787 |
| 2011-06-01 | 1.6923 | 22 | 13 | 479,885 | 191,644 |
| 2011-03-01 | 0.9487 | 74 | 78 | 3,349,957 | 298,759 |
| 2010-12-01 | 0.0734 | 8 | 109 | 535,188 | 5,903,796 |
| 2010-09-01 | 0.2557 | 45 | 176 | 6,551,121 | 7,080,122 |
| 2010-06-01 | 0.4084 | 78 | 191 | 10,982,254 | 6,661,521 |
| 2010-03-01 | 0.6447 | 98 | 152 | 7,098,631 | 5,894,169 |
| 2009-12-01 | 0.4386 | 50 | 114 | 2,794,959 | 9,860,765 |
| 2009-09-01 | 0.7451 | 38 | 51 | 1,736,587 | 3,418,231 |
| 2009-06-01 | 0.661 | 39 | 59 | 1,055,657 | 4,356,189 |
| 2009-03-01 | 0.5865 | 78 | 133 | 6,491,988 | 10,942,940 |
| 2008-12-01 | 0.3716 | 55 | 148 | 4,118,934 | 61,475,535 |
| 2008-09-01 | 0.9167 | 33 | 36 | 1,574,081 | 335,261 |
| 2008-06-01 | 1.56 | 39 | 25 | 1,590,011 | 1,176,869 |
| 2008-03-01 | 7.2857 | 51 | 7 | 4,200,753 | 181,999 |
| 2007-12-01 | 0.5789 | 11 | 19 | 168,165 | 367,270 |
| 2007-09-01 | 0.7143 | 25 | 35 | 267,521 | 28,355,192 |
| 2007-06-01 | 0.1413 | 38 | 269 | 5,398,243 | 24,845,411 |
| 2007-03-01 | 10.0 | 10 | 1 | 149,350 | 11,200 |
| 2006-12-01 | 5.6667 | 17 | 3 | 699,848 | 15,700,950 |
| 2006-09-01 | 12.5 | 25 | 2 | 552,288 | 16,127,050 |
| 2006-06-01 | 3.6667 | 44 | 12 | 1,061,920 | 493,031 |
| 2006-03-01 | 3.1 | 31 | 10 | 2,524,053 | 47,069 |
| 2005-12-01 | 1.4 | 7 | 5 | 9,758 | 13,198 |
| 2005-09-01 | 8.25 | 33 | 4 | 1,954,192 | 52,000 |
| 2005-06-01 | 0.7544 | 43 | 57 | 1,119,693 | 1,495,058 |
| 2005-03-01 | 1.3158 | 25 | 19 | 1,472,940 | 213,586 |
| 2004-12-01 | 0.4333 | 13 | 30 | 366,706 | 446,334 |
| 2004-09-01 | 1.1765 | 20 | 17 | 204,019 | 256,666 |
| 2004-06-01 | 0.2673 | 54 | 202 | 2,053,373 | 4,987,067 |
| 2004-03-01 | 0.3103 | 36 | 116 | 1,984,939 | 4,300,416 |
| 2003-12-01 | 0.1103 | 46 | 417 | 2,364,200 | 2,961,368 |
| 2003-09-01 | 0.0181 | 11 | 607 | 1,077,898 | 1,926,960 |
| 2003-06-01 | 5.0 | 5 | 1 | 1,078 | 27,000 |
Boston Scientific Notable Stakeholders
A Boston Scientific stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Boston Scientific often face trade-offs trying to please all of them. Boston Scientific's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Boston Scientific's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Mahoney | Chairman of the Board, President, Chief Executive Officer | Profile | |
| Kevin Ballinger | Executive Vice President and Global President - Interventional Cardiology | Profile | |
| Desiree RallsMorrison | Senior Vice President General Counsel, Corporate Secretary | Profile | |
| Maulik Nanavaty | Senior Vice President and President - Neuromodulation | Profile | |
| Ian Meredith | Executive Vice President Global Chief Medical Officer | Profile | |
| David Pierce | Executive Vice President and President, MedSurg and President - Endoscopy | Profile | |
| Joseph Fitzgerald | Executive Vice President, President, Interventional Cardiology | Profile | |
| Eric Thepaut | Executive Vice President and President - Europe, Middle East and Africa | Profile | |
| Wendy Carruthers | Executive Vice President - Human Resources | Profile | |
| Jodi Eddy | Senior Vice President and Chief Information and Digital Officer | Profile | |
| John Sorenson | Senior Vice President - Manufacturing and Supply Chain | Profile | |
| Arthur Butcher | Executive Vice President and President, Asia Pacific | Profile | |
| Edward Mackey | Executive Vice President - Global Operations | Profile | |
| Scott Olson | Senior Vice President, President - Cardiac Rhythm Management and Diagnostics | Profile | |
| Jeffrey Mirviss | Executive Vice President and President - Peripheral Interventions | Profile | |
| Jonathan Monson | Chief Accounting Officer, Vice President Global Controller | Profile | |
| Meghan Scanlon | Senior Vice President and President - Urology and Pelvic Health | Profile | |
| Daniel Brennan | CFO, Principal Accounting Officer and Executive VP | Profile | |
| Daniel CPA | Executive CFO | Profile | |
| Edward Ludwig | Lead Independent Director | Profile | |
| Donna James | Independent Director | Profile | |
| Stephen MacMillan | Independent Director | Profile | |
| Ellen Zane | Independent Director | Profile | |
| Nelda Connors | Independent Director | Profile | |
| Charles Dockendorff | Independent Director | Profile | |
| John Sununu | Independent Director | Profile | |
| Yoshiaki Fujimori | Independent Director | Profile | |
| David Wichmann | Independent Director | Profile | |
| David Roux | Independent Director | Profile | |
| Emily Woodworth | Global VP | Profile | |
| Vance JD | General VP | Profile | |
| Susan Lisa | VP, Investor Relations | Profile | |
| Brenda Becker | Senior Affairs | Profile | |
| Miriam Osullivan | Senior Officer | Profile | |
| Catherine Jennings | VP Interventions | Profile | |
| MD FACC | Senior Officer | Profile | |
| Vance Brown | Senior Vice President General Counsel, Corporate Secretary | Profile | |
| Mary Moynihan | Senior Officer | Profile | |
| Jeffrey MBA | Executive Interventions | Profile |
About Boston Scientific Management Performance
The success or failure of an entity such as Boston Scientific Corp often depends on how effective the management is. Boston Scientific management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Boston management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Boston management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.12 | |
| Return On Capital Employed | 0.08 | 0.13 | |
| Return On Assets | 0.05 | 0.05 | |
| Return On Equity | 0.09 | 0.07 |
Please note, the imprecision that can be found in Boston Scientific's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Boston Scientific Corp. Check Boston Scientific's Beneish M Score to see the likelihood of Boston Scientific's management manipulating its earnings.
Boston Scientific Workforce Analysis
Traditionally, organizations such as Boston Scientific use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Boston Scientific within its industry.Boston Scientific Manpower Efficiency
Return on Boston Scientific Manpower
| Revenue Per Employee | 316K | |
| Revenue Per Executive | 429.4M | |
| Net Income Per Employee | 34.8K | |
| Net Income Per Executive | 47.3M | |
| Working Capital Per Employee | 9.8K | |
| Working Capital Per Executive | 13.4M |
Additional Tools for Boston Stock Analysis
When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.